Medscape

Intramuscular Aripiprazole May Be Effective Against Acute Agitation in Psychosis

Oct. 13, 2004 (Stockholm) — The atypical antipsychotic aripiprazole (Abilify) is as effective as haloperidol and significantly more effective than placebo at treating acute agitation in psychotic ...
Business Wire

Clinical Study Shows Intramuscular Administration of Aripiprazole (ABILIFY(R)) Significantly Improves Acute Agitation in Patients With Schizophrenia

NEW YORK-- (BUSINESS WIRE)--Patients with schizophrenia, schizoaffective and schizophreniform disorders who received treatment with intramuscular (IM) administration of aripiprazole (ABILIFY (R)) ...
Business Wire

Results from a Phase 3 Study of Once-Monthly Aripiprazole Intramuscular (IM) Depot Formulation for the Maintenance Treatment of Schizophrenia Presented at APA Annual Meeting ...

Data from Phase 3 Trial demonstrated improvement in time to relapse, the primary efficacy endpoint, for patients receiving once-monthly aripiprazole IM depot formulation compared to placebo Results ...
FiercePharma

U.S. FDA Approves Dual-Chamber Syringe for Abilify Maintena® (aripiprazole) Extended-Release Injectable Suspension for the Treatment of Schizophrenia

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) and Lundbeck announced today that the U.S. Food and Drug Administration (FDA) ...
FiercePharma

FDA Approves Deltoid Injection Site for Abilify Maintena® (aripiprazole) for extended-release injectable suspension in the Treatment of Schizophrenia

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka America Pharmaceutical, Inc. (OAPI) and Lundbeck today announced that the U.S. Food and Drug Administration (FDA) has expanded the label of ...
FierceBiotech

PRESS RELEASE: FDA Approves Otsuka Pharmaceutical and Bristol-Myers Squibb's ABILIFY for Adolescent Patients With Schizophrenia

TOKYO and PRINCETON, N.J., Nov. 6 -- Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY - News) announced today that the U.S. Food and Drug Administration (FDA) approved the ...
Monthly Prescribing Reference

Aripiprazole 2-Month Under Review for Schizophrenia, Bipolar I Disorder

The NDA is supported by data from a phase 1/2 trial that compared the investigational aripiprazole 2-month, long-acting injectable to aripiprazole 1-month depot. The Food and Drug Administration (FDA) ...
Healthline

Abilify Overview

Abilify (aripiprazole) is a prescription drug used to treat schizophrenia and other mental health conditions. Abilify comes as a tablet that you swallow. Abilify contains the active ingredient ...